<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21678">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01872312</url>
  </required_header>
  <id_info>
    <org_study_id>2012H0033</org_study_id>
    <nct_id>NCT01872312</nct_id>
  </id_info>
  <brief_title>Spiration IBV® Valve System and Spiration Airway Sizing Kit</brief_title>
  <official_title>The Humanatarian Use of the Spiration IBV® Valve System and Spiration Airway Sizing Kit for Use in Patients at The Ohio State University Medical Center.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaheen Islam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Spiration, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This procedure allows patients to use the Humanitarian Use Device, IBV® Valve System.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IBV® Valve System The Spiration® IBV Valve System is a device to control prolonged air leaks
      of the lung, or significant air leaks that are likely to become prolonged air leaks
      following lobectomy, segmentectomy, or lung volume reduction surgery (LVRS). An air leak
      present on postoperative day 7 is considered prolonged unless present only during forced
      exhalation or cough. An air leak present on day 5 should be considered for treatment if it
      is: 1) continuous, 2) present during normal inhalation phase of inspiration, or 3) present
      upon normal expiration and accompanied by subcutaneous emphysema or respiratory compromise.
      IBV Valve System use is limited to 6 weeks per prolonged air leak.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>resolution of BPF (Bronchopleural Fistulae)</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>expected resolution of BPF (Bronchopleural Fistulae) in three weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>resolutin of BPF</measure>
    <time_frame>6 weeks</time_frame>
    <description>anticipated the with the use of valves the BPF would improve and the valves can be removed in 6 weeks</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Management of BPF (Bronchopleural Fistulae)</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Loading IBV® Valve System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>treatment with valves (The Spiration® IBV Valve System)</intervention_name>
    <description>treat BPF</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>spiration valve</other_name>
    <other_name>IBV Valve System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresolved BPF

          -  Not candidate for surgical repair
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>shaheen Islam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa Michetti</last_name>
    <phone>6142938000</phone>
    <email>melissa.michetti@osumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>OSUMC</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Michetti</last_name>
    </contact>
    <investigator>
      <last_name>Shaheen Islam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 7, 2014</lastchanged_date>
  <firstreceived_date>April 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Ohio State University</investigator_affiliation>
    <investigator_full_name>Shaheen Islam</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>BPF(Bronchopleural fistulae)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
